OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

1. UroGen reports nearly four-year response duration for JELMYTO in LG-UTUC treatment. 2. Positive long-term results could enhance JELMYTO’s market position and investor confidence.

Research Analysis

2m saved

Insight

Article

FAQ

Why Bullish?

Long-term efficacy data typically boosts investor confidence and stock performance. Historical examples include companies like Novavax, which saw price surges after positive trial results.

How important is it?

The reported efficacy strengthens JELMYTO’s position in the cancer treatment market, enhancing commercial opportunity and investor appeal.

Why Long Term?

Sustained positive outcomes in clinical studies indicate potential for future revenue growth. Past similar occurrences have led to long-term stock appreciation in biotech firms.

Related Companies

NVAX FOLD CRMD

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achie.

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News